EU nod for new formulation of Biogen's Tysabri
A subcutaneous formulation will now be available to treat relapsing-remitting multiple sclerosis
9th April 2021
Latest news
NICE 'no' for Opdivo/Yervoy lung cancer combo
The combination is not considered to be a cost-effective use of NHS resources in this setting
9th April 2021
Human trials for world's first AI-designed immuno-oncology drug
The drug was discovered through an AI-design platform within just eight months of project initiation
9th April 2021
Lilly, Incyte's Olumiant fails in COVID-19 trial
The drug failed to significantly reduce progression to ventilation or death in patients hospitalised with COVID-19
9th April 2021
Achilles' US IPO closed with proceeds of $175m
The Cancer Research UK spinout is developing precision T cell therapies to treat multiple cancers
8th April 2021
Novartis bags EU, UK licences for MS therapy Kesimpta
Kesimpta is the first self-administered B-cell therapy for patients with relapsing forms of multiple sclerosis
8th April 2021
Benefits of AZ vaccine outweigh risks, says MHRA
The risk of rare blood clots is currently calculated at four people in a million who receive the vaccine
8th April 2021
Coronavirus infections drop but R number remains at 1
Data suggest infections in England fell by 60% from February, but the decline is levelling
8th April 2021
Novartis UK announces further HRT patch stock issues
Supplies of Estradot TTS-75 are expected to return to normal within eight weeks
7th April 2021
Nationwide launch for pioneering fertility study
The NIHR-funded trial will assess whether removing small fibroids and endometrial polyps improves fertility and live births
7th April 2021
Artios, Novartis form cancer therapies collaboration
The deal could be worth as much as $1.3 billion to Artios
7th April 2021
Fund opens to boost UK life sciences manufacturing
The £20 million fund will boost the UK's life sciences manufacturing capabilities, creating new economic opportunities and highly skilled jobs
7th April 2021
UK rolls out Moderna's COVID vaccine
The vaccine is the third to be approved for use in the UK to protect against COVID-19
7th April 2021
PharmaTimes announces the launch of the Communications Awards for 2021
The 2021 Communications Awards have opened their doors for entry, inviting the very best in pharma communications to come forward and claim first prize.
6th April 2021
NICE backs restricted use of Ondexxya
Funding backed for reversal of gastrointestinal bleeds but not for intracranial haemorrhage
6th April 2021
